Some effects of combination chemotherapy with cis‐platinum on renal function in patients with nonseminomatous testicular carcinoma

68Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Renal function in 24 patients with disseminated nonseminomatous testicular carcinoma treated with combination chemotherapy including cis‐platinum was examined prospectively. Renal function was monitored by several determinations of glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and serum creatinine, and beta‐2‐microglobulin. A reduction in GFR and ERPF was found at the end of the induction chemotherapy and at six weeks thereafter. Median GFR and ERPF decreased both 23% (P < 0.01). Serum creatinine and beta‐2‐microglobulin concentrations however did not rise. It is suggested that under the influence of chemotherapy with platinum the production of creatinine and beta‐2‐microglobulin is decreased rendering their serum levels unsuitable as parameters of renal function. Copyright © 1983 American Cancer Society

Cite

CITATION STYLE

APA

Meijer, S., Sleijfer, D. T., Mulder, N. H., Sluiter, W. J., Marrink, J., Koops, H. S., … Mandema, E. (1983). Some effects of combination chemotherapy with cis‐platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer, 51(11), 2035–2040. https://doi.org/10.1002/1097-0142(19830601)51:11<2035::AID-CNCR2820511113>3.0.CO;2-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free